Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment

被引：0
|
作者：
Post, F. [1 ]
Andrade-Villanueva, J. [2 ]
Fisher, M. [3 ]
Winston, J. [4 ]
Liu, Y. [5 ]
Zhong, L. [5 ]
Cheng, A. [5 ]
Rhee, M. [5 ]
Szwarcberg, J. [5 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Hosp Civil Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
[3] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England
[4] Mt Sinai Sch Med, New York, NY USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2014年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [1] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment
    Post, Frank A.
    Winston, Jonathan
    Andrade-Villanueva, Jaime F.
    Fisher, Martin
    Liu, YaPei
    Beraud, Christophe
    Abram, Michael E.
    Graham, Hiba
    Rhee, Martin S.
    Cheng, Andrew K.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (03) : 310 - 313
  • [2] Reports of viral hepatitis B and C in HIV patients participating in clinical trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-boosted atazanavir plus tenofovir DF/emtricitabine
    Quirk, E.
    Graham, H.
    Liu, C.
    Rhee, M.
    Piontkowsky, D.
    Szwarcberg, J.
    ANTIVIRAL THERAPY, 2013, 18 : A63 - A63
  • [3] Resistance analyses of the elvitegravir/cobicistat/emtricitabine/tenofovir DF switch studies
    Andreatta, K.
    Kulkarni, R.
    Abram, M. E.
    Nguyen, T.
    Cao, H.
    Miller, M. D.
    White, K. L.
    ANTIVIRAL THERAPY, 2014, 19 : A144 - A144
  • [4] Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
    White, Kirsten L.
    Kulkarni, Rima
    McColl, Damian J.
    Rhee, Martin S.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    ANTIVIRAL THERAPY, 2015, 20 (03) : 317 - 327
  • [5] Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults
    Bonora, Stefano
    Calcagno, Andrea
    Trentalange, Alice
    Di Perri, Giovanni
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 409 - 419
  • [6] Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV
    Imaz, Arkaitz
    Podzamczer, Daniel
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2017, 15 (03) : 195 - 209
  • [7] Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients
    Calcagno, Andrea
    Simiele, Marco
    Motta, Ilaria
    Pinna, Simone Mornese
    Bertucci, Roberto
    D'Avolio, Antonio
    Di Perri, Giovanni
    Bonora, Stefano
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (05) : 409 - 411
  • [8] Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
    Kulkarni, Rima
    Abram, Michael E.
    McColl, Damian J.
    Barnes, Tiffany
    Fordyce, Marshall W.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    White, Kirsten L.
    HIV CLINICAL TRIALS, 2014, 15 (05): : 218 - 229
  • [9] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideRebound of HIV infection: case report
    Reactions Weekly, 2020, 1828 (1) : 155 - 155
  • [10] Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamideReduced susceptibility to elvitegravir : case report
    Reactions Weekly, 2016, 1617 (1) : 72 - 72
12345